Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis

OBJECTIVES: To examine whether treatment with anti‐tumour necrosis factor (TNF) α prevents loss of bone mineral density (BMD) at the spine and hip (generalised) and in the hands (local) of patients with rheumatoid arthritis, and to study the changes in markers of bone metabolism, including receptor...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Vis, M, Havaardsholm, E A, Haugeberg, G, Uhlig, T, Voskuyl, A E, van de Stadt, R J, Dijkmans, B A C, Woolf, A D, Kvien, T K, Lems, W F
Format: Artigo
Jezik:Inglês
Izdano: BMJ Group 2006
Teme:
Extended Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1798341/
https://ncbi.nlm.nih.gov/pubmed/16606653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2005.044198
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items